256 related articles for article (PubMed ID: 25201005)
1. Lupus anticoagulant and thrombosis in splenic marginal zone lymphoma.
Gebhart J; Lechner K; Skrabs C; Sliwa T; Müldür E; Ludwig H; Nösslinger T; Vanura K; Stamatopoulos K; Simonitsch-Klupp I; Chott A; Quehenberger P; Mitterbauer-Hohendanner G; Pabinger I; Jäger U; Geissler K
Thromb Res; 2014 Nov; 134(5):980-4. PubMed ID: 25201005
[TBL] [Abstract][Full Text] [Related]
2. Splenic marginal zone lymphoma: Prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab era.
Perrone S; D'Elia GM; Annechini G; Ferretti A; Tosti ME; Foà R; Pulsoni A
Leuk Res; 2016 May; 44():53-60. PubMed ID: 27030961
[TBL] [Abstract][Full Text] [Related]
3. [Splenic marginal zone lymphoma associated with antiphospholipid antibodies].
Yokoi T; Mori S; Sugimoto H; Komiyama Y; Uemura Y; Tanijiri R; Nakai K; Matsumoto N; Zen K; Amakawa R; Kishimoto Y; Ieko M; Takahashi H; Fukuhara S
Rinsho Ketsueki; 2004 Oct; 45(10):1095-9. PubMed ID: 15553043
[TBL] [Abstract][Full Text] [Related]
4. [Splenic marginal zone lymphoma associated with autoimmune hemolytic anemia treated with splenectomy and rituximab].
Miztani M; Noda T; Umino A; Tanigawa M; Taniguchi M; Tamaki S; Tsuji K
Rinsho Ketsueki; 2007 Nov; 48(11):1489-91. PubMed ID: 18080507
[TBL] [Abstract][Full Text] [Related]
5. Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma.
Olszewski AJ; Ali S
Ann Hematol; 2014 Mar; 93(3):449-58. PubMed ID: 24057925
[TBL] [Abstract][Full Text] [Related]
6. Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab.
Bennett M; Schechter GP
Semin Hematol; 2010 Apr; 47(2):143-7. PubMed ID: 20350661
[TBL] [Abstract][Full Text] [Related]
7. Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia.
Xing KH; Kahlon A; Skinnider BF; Connors JM; Gascoyne RD; Sehn LH; Savage KJ; Slack GW; Shenkier TN; Klasa R; Gerrie AS; Villa D
Br J Haematol; 2015 May; 169(4):520-7. PubMed ID: 25854936
[TBL] [Abstract][Full Text] [Related]
8. [Clinicopathologic study of splenic marginal zone B-cell lymphoma].
Zhang YN; Zheng YY; Zhou XG; Zhang SH; Jin Y; Xie JL; Chen SY; Shi Y; Wu LH
Zhonghua Bing Li Xue Za Zhi; 2009 Apr; 38(4):243-7. PubMed ID: 19575895
[TBL] [Abstract][Full Text] [Related]
9. Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma.
Else M; Marín-Niebla A; de la Cruz F; Batty P; Ríos E; Dearden CE; Catovsky D; Matutes E
Br J Haematol; 2012 Nov; 159(3):322-8. PubMed ID: 23016878
[TBL] [Abstract][Full Text] [Related]
10. Autoimmune hemolytic anemia as a risk factor of poor outcome in patients with splenic marginal zone lymphoma.
Fodor A; Molnar MZ; Krenacs L; Bagdi E; Csomor J; Matolcsy A; Demeter J
Pathol Oncol Res; 2009 Dec; 15(4):597-603. PubMed ID: 19343544
[TBL] [Abstract][Full Text] [Related]
11. [Splenic marginal zone lymphoma].
Dimopoulos K; Pedersen M
Ugeskr Laeger; 2012 Oct; 174(40):2383-6. PubMed ID: 23031300
[TBL] [Abstract][Full Text] [Related]
12. Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy.
Kalpadakis C; Pangalis GA; Angelopoulou MK; Sachanas S; Kontopidou FN; Yiakoumis X; Kokoris SI; Dimitriadou EM; Dimopoulou MN; Moschogiannis M; Korkolopoulou P; Kyrtsonis MC; Siakantaris MP; Papadaki T; Tsaftaridis P; Plata E; Papadaki HE; Vassilakopoulos TP
Oncologist; 2013; 18(2):190-7. PubMed ID: 23345547
[TBL] [Abstract][Full Text] [Related]
13. Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients.
Thieblemont C; Felman P; Berger F; Dumontet C; Arnaud P; Hequet O; Arcache J; Callet-Bauchu E; Salles G; Coiffier B
Clin Lymphoma; 2002 Jun; 3(1):41-7. PubMed ID: 12141954
[TBL] [Abstract][Full Text] [Related]
14. Splenic marginal zone lymphoma: disease features and management.
Matutes E
Expert Rev Hematol; 2013 Dec; 6(6):735-45. PubMed ID: 24168526
[TBL] [Abstract][Full Text] [Related]
15. [Splenic marginal zone lymphoma and autoimmunity: report of six cases].
Voinchet H; Etienne G; Ghiringelli CB; Pellegrin JL; Viallard JF; Parrens M; Longy-Boursier M
Rev Med Interne; 2010 Jan; 31(1):4-11. PubMed ID: 19589627
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.
Iannitto E; Bellei M; Amorim S; Ferreri AJM; Marcheselli L; Cesaretti M; Haioun C; Mancuso S; Bouabdallah K; Gressin R; Tripodo C; Traverse-Glehen A; Baseggio L; Zupo S; Stelitano C; Castagnari B; Patti C; Alvarez I; Liberati AM; Merli M; Gini G; Cabras MG; Dupuis J; Tessoulin B; Perrot A; Re F; Palombi F; Gulino A; Zucca E; Federico M; Thieblemont C
Br J Haematol; 2018 Dec; 183(5):755-765. PubMed ID: 30407629
[TBL] [Abstract][Full Text] [Related]
17. Significant efficacy of 2-chlorodeoxyadenosine{+/-} rituximab in the treatment of splenic marginal zone lymphoma (SMZL): extended follow-up.
Cervetti G; Galimberti S; Pelosini M; Ghio F; Cecconi N; Petrini M
Ann Oncol; 2013 Sep; 24(9):2434-8. PubMed ID: 23712547
[TBL] [Abstract][Full Text] [Related]
18. Treatment of splenic marginal zone lymphoma: should splenectomy be abandoned?
Kalpadakis C; Pangalis GA; Vassilakopoulos TP; Sachanas S; Angelopoulou MK
Leuk Lymphoma; 2014 Jul; 55(7):1463-70. PubMed ID: 24050506
[TBL] [Abstract][Full Text] [Related]
19. No evidence of splenic disease in patients with splenic marginal zone lymphoma undergoing splenectomy for autoimmune hemolytic anemia after monotherapy with rituximab.
Kalpadakis C; Pangalis GA; Sachanas S; Rontogianni D; Korkolopoulou P; Milionis V; Vassilakopoulos TP; Papadaki HA; Angelopoulou MK
Leuk Lymphoma; 2016 Nov; 57(11):2705-8. PubMed ID: 27082039
[No Abstract] [Full Text] [Related]
20. Early-stage splenic diffuse large B-cell lymphoma is highly associated with hepatitis C virus infection.
Yu SC; Lin CW
Kaohsiung J Med Sci; 2013 Mar; 29(3):150-6. PubMed ID: 23465418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]